agilon health, inc. (AGL) stock plummeted 16.25% in the after-hours trading session on Tuesday, following the company's disappointing fourth quarter 2024 earnings results and weak guidance for the upcoming fiscal year 2025.
While the healthcare services company reported revenue of $1.52 billion for Q4 2024, in line with expectations, its earnings metrics fell short. agilon health reported an adjusted loss of $0.26 per share, wider than analysts' estimates of a $0.23 per share loss. More concerningly, the company's adjusted EBITDA of -$83.97 million significantly lagged expectations of -$69.92 million.
Perhaps more worrisome for investors was agilon health's outlook for fiscal 2025. The company provided revenue growth guidance of just -2.2% year-over-year at the midpoint, a sharp deceleration from the 40.7% growth achieved in fiscal 2024. agilon health's projected 2025 EBITDA guidance of -$75 million also fell short of analyst expectations, highlighting continued profitability challenges amid what management termed a "challenging Medicare Advantage environment."
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。